Zogenix, Inc. (NASDAQ:ZGNX) Short Interest Update

Zogenix, Inc. (NASDAQ:ZGNX) saw a large growth in short interest in June. As of June 15th, there was short interest totalling 9,030,200 shares, a growth of 6.9% from the May 15th total of 8,444,100 shares. Based on an average daily trading volume, of 733,300 shares, the short-interest ratio is presently 12.3 days. Approximately 22.8% of the shares of the stock are sold short.

In other news, insider Stephen J. Farr sold 34,225 shares of the business’s stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $48.01, for a total transaction of $1,643,142.25. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Michael P. Smith sold 15,000 shares of the business’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $46.32, for a total value of $694,800.00. The disclosure for this sale can be found here. 4.40% of the stock is currently owned by insiders.

Several hedge funds have recently bought and sold shares of ZGNX. FMR LLC lifted its stake in shares of Zogenix by 225.2% in the 4th quarter. FMR LLC now owns 4,184,131 shares of the company’s stock valued at $152,553,000 after purchasing an additional 2,897,392 shares during the period. Great Point Partners LLC acquired a new stake in Zogenix during the 4th quarter worth $36,460,000. venBio Select Advisor LLC raised its stake in Zogenix by 35.5% during the 4th quarter. venBio Select Advisor LLC now owns 1,975,000 shares of the company’s stock worth $72,009,000 after buying an additional 517,087 shares during the period. RA Capital Management LLC raised its stake in Zogenix by 26.8% during the 4th quarter. RA Capital Management LLC now owns 2,382,168 shares of the company’s stock worth $86,854,000 after buying an additional 503,400 shares during the period. Finally, Marshall Wace LLP raised its stake in Zogenix by 321.4% during the 1st quarter. Marshall Wace LLP now owns 564,721 shares of the company’s stock worth $31,065,000 after buying an additional 430,698 shares during the period.

A number of research analysts have recently weighed in on ZGNX shares. LADENBURG THALM/SH SH set a $50.00 price target on Zogenix and gave the company a “buy” rating in a report on Tuesday, April 9th. Guggenheim started coverage on Alteryx in a research note on Thursday, June 27th. They issued a “buy” rating and a $107.53 target price on the stock. BidaskClub downgraded ZIX from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 7th. William Blair restated a “buy” rating on shares of Rocket Pharmaceuticals in a research note on Tuesday, April 9th. Finally, Piper Jaffray Companies set a $55.00 target price on Pacira Biosciences and gave the company a “buy” rating in a research note on Tuesday, April 9th. One investment analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. Zogenix currently has a consensus rating of “Buy” and an average price target of $62.92.

NASDAQ ZGNX traded up $0.05 during trading hours on Friday, reaching $47.95. 414,145 shares of the company’s stock were exchanged, compared to its average volume of 675,428. The company has a market cap of $2.04 billion, a PE ratio of -14.85 and a beta of 2.04. Zogenix has a one year low of $33.43 and a one year high of $59.85. The business’s fifty day simple moving average is $43.23. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.12 and a current ratio of 9.12.

Zogenix (NASDAQ:ZGNX) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.83) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.85) by $0.02. On average, equities analysts forecast that Zogenix will post -3.69 earnings per share for the current fiscal year.

Zogenix Company Profile

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

See Also: What are the reasons investors use put options?

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.